A provision in Nevada's new prescription drug bill limits what small manufacturers can be charged for certain medications—and creates legal exposure if suppliers try to charge more.
Most Nevada manufacturing owners don't realize that a provision buried in AB259 fundamentally changes how their business can be charged for certain prescription drugs. And that change takes effect January 1, 2026.
Here's what's happening: Nevada law now prohibits small businesses—including manufacturers—from paying more than Medicare's maximum fair price for any drug subject to federal price negotiation. That's a hard cap. No exceptions based on volume, contract terms, or supplier preference.
If your business purchases prescription drugs covered by Medicare's negotiated maximum fair price program, this applies to you. The law covers any entity that buys these drugs, not just health plans or pharmacies. That includes manufacturers who provide employee health benefits or purchase medications for workplace use.
Under Section 1 of AB259 (Page 3), any supplier or vendor who charges your business more than the federally negotiated maximum fair price for a covered drug is committing a deceptive trade practice under Nevada law. That's the legal language that matters.
If a supplier violates this, your business has two paths:
Civil penalties: Up to $15,000 per violation. A single overcharge could trigger this.
Private lawsuits: You can sue for consumer fraud, and if you win, the supplier pays your attorney fees. This creates real financial incentive for suppliers to comply—and for your business to enforce it.
The law becomes effective January 1, 2026, for all operative purposes. One important detail: the price cap does not apply to contracts your business entered into before January 1, 2026. If you have existing drug supply agreements, they're grandfathered in. But any new contracts or renewals after that date fall under the cap.
Before 2026, review any prescription drug supply agreements your business has. Understand which drugs in those contracts are subject to Medicare price negotiation. When contracts renew or new ones are negotiated after January 1, 2026, ensure pricing reflects the federally negotiated maximum fair price—not higher.
If a supplier tries to charge above that price after the effective date, document it. You have legal recourse, and the law is designed to make that recourse meaningful.
This provision is relatively quiet in AB259, but for manufacturers managing employee health costs or purchasing drugs for workplace purposes, it's a material change in your negotiating position with suppliers.
Source: Nevada AB259 (BDR 40-165), Section 1, Page 3. Effective January 1, 2026.